SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
In conclusion, Ibrutinib has brought a major advance in the treatment of CLL. Nonetheless,
there are some patients who might benefit more from alternate treatments notably in
frontline. Moreover, Ibrutinib tolerability is very dependent on the awareness of treating
physician and patient on adverse events and co-medications. References
References
1- Woyach J et al NEJM 2018
2- Moreno C et al, Lancet Oncol 2019
3- Shanafelt T et al, NEJM 2019
4- Fischer K, et al. Blood 2016;;
5- Eichhorst BF, et al. Lancet Oncol. 2016
6- Thompson PA, Blood. 2016;
7- Chai-Adisaksopha C , Blood 2017
8- Gribben BJH 2018
9- Shatzel JTH 2017
10- Ghez D Blood 2018
11- Fischer K NEJM 2019